<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>325</serviceExecutionTime><Drug id="58398"><DrugName>PS-178990</DrugName><DrugSynonyms><Name><Value>SARMs (muscle wasting disease), Pharmacopeia</Value></Name><Name><Value>selective androgen receptor modulators (muscle wasting disease), Pharmacopeia</Value></Name><Name><Value>SARMs (muscle wasting disease), BMS</Value></Name><Name><Value>selective androgen receptor modulators (muscle wasting disease), BMS</Value></Name><Name><Value>PS-178990</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SARMs (muscle wasting disease), Ligand </Value></Name><Name><Value>selective androgen receptor modulators (muscle wasting disease), Ligand</Value></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="17808">Ligand Pharmaceuticals Inc</Company><Company id="19062">Pharmacopeia Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="58398" type="Drug"><TargetEntity id="462912" type="siDrug">PS-178990</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="17808" type="Company"><TargetEntity id="4295907009" type="organizationId">Ligand Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="19062" type="Company"><TargetEntity id="4295907284" type="organizationId">Pharmacopeia Inc</TargetEntity></SourceEntity><SourceEntity id="407" type="ciIndication"><TargetEntity id="1750" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="836" type="Action"><TargetEntity id="2877" type="Mechanism">Drugs Acting on Androgen Receptor</TargetEntity><TargetEntity id="1476" type="Mechanism">Androgen Receptor Ligands</TargetEntity><TargetEntity id="1149" type="Mechanism">Selective Androgen Receptor Modulators (SARM)</TargetEntity><TargetEntity id="2876" type="Mechanism">Androgen Receptor Degradation Enhancers</TargetEntity></SourceEntity><SourceEntity id="PTGT-00135" type="ciTarget"><TargetEntity id="9904399853673" type="siTarget">Androgen receptor</TargetEntity><TargetEntity id="4423" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="407">Muscle wasting disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="836">Androgen receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1408">Muscle system agent</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-21T12:34:07.000Z</LastModificationDate><ChangeDateLast>2011-12-03T04:14:25.000Z</ChangeDateLast><AddedDate>2007-10-16T15:23:28.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17808" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) was developing PS-178990, the lead in a series of selective androgen receptor modulators (SARMs), and its follow-up compounds, for the potential treatment of muscle wasting disease associated with a range of conditions [&lt;ulink linkID="839103" linkType="Reference"&gt;839103&lt;/ulink&gt;], [&lt;ulink linkID="1086885" linkType="Reference"&gt;1086885&lt;/ulink&gt;]. In October 2007, a single-dose-escalating phase I study had been completed [&lt;ulink linkID="839103" linkType="Reference"&gt;839103&lt;/ulink&gt;]. In December 2009, the program was still in phase I development [&lt;ulink linkID="1086885" linkType="Reference"&gt;1086885&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17808" linkType="Company"&gt;Ligand Pharmaceuticals&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="19062" linkType="Company"&gt;Pharmacopeia&lt;/ulink&gt;, under license from BMS, was  previously developing PS-178990  for  muscle wasting disease associated with a range of conditions. By November 2007, Pharmacopeia planned to conduct several phase I studies of PS-178990 during 2008 [&lt;ulink linkID="846662" linkType="Reference"&gt;846662&lt;/ulink&gt;], [&lt;ulink linkID="1086885" linkType="Reference"&gt;1086885&lt;/ulink&gt;]. In May 2008, phase II trials were planned for the first half of 2009 [&lt;ulink linkID="911476" linkType="Reference"&gt;911476&lt;/ulink&gt;]. However, in December 2009, BMS reacquired all rights for the program from Ligand [&lt;ulink linkID="1086885" linkType="Reference"&gt;1086885&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;BMS was also developing other SARMs, including &lt;ulink linkID="46640" linkType="Drug"&gt;BMS-641988&lt;/ulink&gt;, for prostate cancer, and  &lt;ulink linkID="49383" linkType="Drug"&gt;BMS-564929&lt;/ulink&gt; for testosterone deficiency.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By November 2007, a phase I single ascending dose study of PS-178990 had been conducted. At this time, the company planned to conduct several phase I studies, including a multiple ascending dose study, during 2008 [&lt;ulink linkID="846662" linkType="Reference"&gt;846662&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2007, Pharmacopeia licensed &lt;ulink linkID="15065" linkType="Company"&gt;&lt;/ulink&gt;BMS's &lt;ulink linkID="58398" linkType="Drug"&gt;&lt;/ulink&gt;SARM series, including PS-178990 and its follow-up compounds. In exchange for the license, Pharmacopeia would apply its medicinal chemistry to BMS' unrelated discovery program for up to 3 years [&lt;ulink linkID="839103" linkType="Reference"&gt;839103&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17808">Ligand Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1086885" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-15T00:00:00.000Z</StatusDate><Source id="1086885" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19062">Pharmacopeia Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-15T00:00:00.000Z</StatusDate><Source id="839103" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-15T00:00:00.000Z</StatusDate><Source id="839103" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17808">Ligand Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="407">Muscle wasting disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-23T00:00:00.000Z</StatusDate><Source id="972879" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00135"><Name>Androgen receptor</Name><SwissprotNumbers><Swissprot>O97775</Swissprot><Swissprot>O97776</Swissprot><Swissprot>O97952</Swissprot><Swissprot>O97960</Swissprot><Swissprot>P10275</Swissprot><Swissprot>P15207</Swissprot><Swissprot>P19091</Swissprot><Swissprot>P49699</Swissprot><Swissprot>Q6QT55</Swissprot><Swissprot>Q7T1K4</Swissprot><Swissprot>Q8MIK0</Swissprot><Swissprot>Q9GKL7</Swissprot><Swissprot>Q9TT90</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17808">Ligand Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110410" title="Pharmacopeia to develop BMS' selective androgen receptor modulators  "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>